Page
%P
![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Open AccessPrediction of plasma ctDNA fraction and prognostic implications of liquid biopsy in advanced prostate cancer
No consensus strategies exist for prognosticating metastatic castration-resistant prostate cancer (mCRPC). Circulating tumor DNA fraction (ctDNA%) is increasingly reported by commercial and laboratory tests bu...
-
Article
Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer
Circulating tumour DNA (ctDNA) in blood plasma is an emerging tool for clinical cancer genoty** and longitudinal disease monitoring1. However, owing to past emphasis on targeted and low-resolution profiling app...